

KAJIAN POTENSI KARAGENAN DARI *Gigartina skottsbergii*
SEBAGAI KANDIDAT ANTIVIRUS SARS-CoV-2 MENGGUNAKAN
SIMULASI *MOLECULAR DOCKING*

SKRIPSI

diajukan untuk memenuhi salah satu syarat memperoleh Gelar Sarjana Sains
Program Studi Kimia



oleh

Diah Nurhayati

NIM 1602265

PROGRAM STUDI KIMIA
DEPARTEMEN PENDIDIKAN KIMIA
FAKULTAS PENDIDIKAN MATEMATIKA DAN ILMU PENGETAHUAN ALAM
UNIVERSITAS PENDIDIKAN INDONESIA
BANDUNG
2020

Diah Nurhayati, 2020

KAJIAN POTENSI KARAGENAN DARI Gigartina skottsbergii SEBAGAI KANDIDAT ANTIVIRUS
SARS-CoV-2 MENGGUNAKAN SIMULASI *MOLECULAR DOCKING*

Universitas Pendidikan Indonesia | repository.upi.edu | perpustakaan.upi.edu

KAJIAN POTENSI KARAGENAN DARI *Gigartina skottsbergii*
SEBAGAI KANDIDAT ANTIVIRUS SARS-CoV-2 MENGGUNAKAN
SIMULASI *MOLECULAR DOCKING*

Oleh
Diah Nurhayati

Skripsi diajukan untuk memenuhi sebagian syarat memperoleh gelar Sarjana
Sains Program Studi Kimia

©Diah Nurhayati 2020
Universitas Pendidikan Indonesia
Agustus 2020

Hak Cipta dilindungi undang-undang

Skripsi ini tidak boleh diperbanyak seluruh atau sebagian, dengan dicetak ulang,
difotokopi, atau cara lainnya tanpa izin dari penulis.

DIAH NURHAYATI

KAJIAN POTENSI KARAGENAN DARI *Gigartina skottsbergii* SEBAGAI
KANDIDAT ANTIVIRUS SARS-CoV-2 MENGGUNAKAN SIMULASI
MOLECULAR DOCKING

disetujui dan disahkan oleh pembimbing :

Pembimbing I



Gun Gun Gumilar, S.Pd., M.Si.
NIP. 197906262001121001

Pembimbing II



Heli Siti Halimatul Munawaroh, Ph.D.
NIP. 197907302001122002

Mengetahui,

Ketua Departemen Pendidikan Kimia FPMIPA UPI



Dr. Hendrawan, M.Si.
NIP. 196309111989011001

ABSTRAK

Pandemi COVID-19 telah mendorong dilakukannya penelitian tentang bahan alam yang berpotensi digunakan sebagai antivirus SARS-CoV-2 (*Severe Acute Respiratory Syndrome Coronavirus 2*). Karagenan dilaporkan memiliki aktivitas antivirus *human coronavirus* OC43, influenza, DENV, HSV-1, HSV-2, HPV, HRV, dan HIV. Salah satu sumber karagenan adalah alga merah *Gigartina skottsbergii*. Penelitian ini bertujuan untuk melakukan *screening* terhadap potensi karagenan sebagai antivirus SARS-CoV-2 menggunakan simulasi *molecular docking*. *Docking* dilakukan untuk tiga jenis karagenan yang terdapat dalam *Gigartina skottsbergii*, yakni λ -, κ -, dan ι -karagenan terhadap reseptor ACE2 dan RBD serta M^{pro} SARS-CoV-2. Sebagai pembanding potensi aktivitas digunakan nelfinavir, klorokuin dan hidroksi-klorokuin yang telah dilaporkan memiliki aktivitas antivirus SARS-CoV-2. Tahapan penelitian meliputi preparasi protein, validasi metode *docking*, preparasi ligan, proses *docking*, dan visualisasi hasil *docking* menggunakan beberapa perangkat lunak diantaranya AutodockTools 1.1.2, AutodockVina 1.5.6, PyMol 2.2.3, dan BIOVIA *Discovery Studio Visualizer* 2020. Hasil simulasi menunjukkan bahwa afinitas κ -karagenan terhadap reseptor ACE2 memiliki ΔG paling tinggi dan mencapai 1,2 *kcal/mol* lebih tinggi dibanding klorokuin. Afinitas κ -karagenan terhadap reseptor RBD SARS-CoV-2 memiliki ΔG paling tinggi dan mencapai 1,5 *kcal/mol* lebih tinggi dibanding klorokuin. Afinitas ι -karagenan terhadap reseptor M^{pro} SARS-CoV-2 memiliki ΔG paling tinggi dan mencapai 1,7 *kcal/mol* lebih tinggi dibanding klorokuin. Sisi pengikatan κ -karagenan pada ACE2 sama dengan hidroksi-klorokuin, sedangkan sisi pengikatan κ -karagenan dan ι -karagenan pada RBD dan M^{pro} SARS-CoV-2 sama dengan semua senyawa pembanding. κ -karagenan dan ι -karagenan berinteraksi dengan ketiga protein melibatkan ikatan hidrogen, elektrostatik dan Van der Waals. Berdasarkan hasil simulasi dapat disimpulkan bahwa κ -karagenan dan ι -karagenan paling berpotensi sebagai kandidat antivirus SARS-CoV-2. Pengujian eksperimental perlu dilakukan untuk mengetahui lebih lanjut efektifitas karagenan sebagai antivirus SARS-CoV-2.

Kata kunci: Antivirus, COVID-19, *Gigartina skottsbergii*, Karagenan, SARS-CoV-2

ABSTRACT

The COVID-19 pandemic has promoted the exploration of the natural compounds that are potential to be used as antiviral for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Antiviral activity of carrageenan has been reported for human coronavirus OC43, influenza, DENV, HSV-1, HSV-2, HPV, HRV, and HIV. Red algae *Gigartina skottsbergii* is rich of carrageenan. Here, this study aims to screen the potential of carrageenan as antiviral for SARS-CoV-2 using molecular *docking* simulations. *Docking* was carried out for three types of carrageenan contained in *Gigartina skottsbergii*, namely λ -, κ -, and ι -carrageenan against ACE2, RBD and M^{PRO} SARS-CoV-2 receptors. The activity of the target compounds was compared to chloroquine, hydroxy-chloroquine, and nelfinavir which have been reported to have potential as antiviral SARS-CoV-2. The steps of the research included protein preparation, *docking* method validation, ligand preparation, *docking* process, and visualization of *docking* results using several software including AutodockTools 1.1.2, AutodockVina 1.5.6, PyMol 2.2.3, and BIOVIA Discovery Studio Visualizer 2020. *Docking* results show that the affinity of κ -carrageenan to the ACE2 receptor had the highest ΔG and was 1,2 kcal/mol higher than chloroquine. The affinity of κ -carrageenan to the RBD SARS-CoV-2 receptor had the highest ΔG and was 1,5 kcal/mol higher than chloroquine. The affinity of ι -carrageenan to the M^{PRO} SARS-CoV-2 receptor has the highest ΔG and is up to 1,7 kcal/mol higher than chloroquine. The binding site of κ -carrageenan on ACE2 was occupied the same cavity as for hydroxy-chloroquine, while the binding sites for κ -carrageenan and ι -carrageenan in RBD and M^{PRO} SARS-CoV-2 were the same as chloroquine, hydroxy-chloroquine, and nelfinavir. Molecular interaction analysis performed that κ -carrageenan and ι -carrageenan interact with all three proteins through hydrogen bond, electrostatic and Van der Waals. Based on the results, it can be concluded that κ -carrageenan and ι -carrageenan show the most potential candidates of antiviral for SARS-CoV-2. Further testing in laboratory needs to be done to experimentally determined the effectiveness of carrageenan as an antiviral SARS-CoV-2.

Keywords: Antiviral, Carrageenan, COVID-19, *Gigartina skottsbergii*, SARS-CoV-2

DAFTAR ISI

KATA PENGANTAR	i
UCAPAN TERIMA KASIH.....	ii
ABSTRAK.....	iv
ABSTRACT.....	v
DAFTAR ISI.....	vi
DAFTAR TABEL.....	ix
DAFTAR GAMBAR	x
DAFTAR LAMPIRAN.....	xi
BAB I PENDAHULUAN.....	1
1.1. Latar Belakang.....	1
1.2. Rumusan Masalah	3
1.3. Tujuan Penelitian.....	4
1.4. Manfaat Penelitian.....	4
1.5. Struktur Organisasi Skripsi.....	5
BAB II KAJIAN PUSTAKA.....	6
2.1. COVID-19 (<i>Coronavirus Disease 2019</i>).....	6
2.2. Virus Corona (CoV)	6
2.3. <i>Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)</i>	7
2.4. Cara Kerja SARS-CoV-2	10
2.5. Obat Antivirus	15
2.6. Klorokuin.....	16
2.7. Nelfinavir.....	17
2.8. Karagenan.....	17
2.9. <i>Gigartina skottsbergii</i>	20
2.10. <i>Molecular Docking</i>	21
2.11. Autodock dan Autodock Vina	23
BAB III METODE PENELITIAN	25
3.1. Waktu dan Lokasi Penelitian.....	25
3.2. Alat dan Bahan	25
3.2.1. Alat.....	25
3.2.2. Bahan	25
3.3. Prosedur Penelitian	25
3.3.1. Validasi Program <i>Docking</i>	26

3.3.2. Preparasi Ligan	27
3.3.3. Preparasi Protein	28
3.3.4. <i>Molecular Docking</i> Protein-Ligan	30
BAB IV TEMUAN DAN PEMBAHASAN	32
4.1. Afinitas Ikatan dan Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan <i>Angiotensin Converting Enzyme 2 (ACE2)</i> Berdasarkan Hasil <i>Molecular Docking</i>	32
4.1.1. Afinitas Ikatan λ -, κ -, dan ι -karagenan dengan ACE2.....	32
4.1.2. Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan ACE2.....	33
4.1.2.1. Visualisasi Sisi Pengikatan λ -, κ -, dan ι -karagenan dengan ACE2.....	33
4.1.2.2. Ikatan dan Interaksi yang Terbentuk antara λ -, κ -, dan ι -karagenan dengan ACE2	35
4.2. Afinitas Ikatan Dan Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan <i>Receptor Binding Domain (RBD) SARS-CoV-2</i> Berdasarkan Hasil <i>Molecular Docking</i>	43
4.2.1 Afinitas Ikatan λ -, κ -, dan ι -karagenan dengan RBD SARS-CoV-2 ..	43
4.2.2 Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan RBD SARS-CoV-2.....	44
4.2.2.1. Visualisasi Sisi Pengikatan λ -, κ -, dan ι -karagenan dengan RBD SARS-CoV-2	44
4.2.2.2. Interaksi yang Terbentuk antara λ -, κ -, dan ι -karagenan dengan RBD SARS-CoV-2	45
4.3. Afinitas Ikatan Dan Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan <i>Main Protease (M^{pro}) SARS-CoV-2</i> Berdasarkan Hasil <i>Molecular Docking</i>	54
4.3.1. Afinitas Ikatan λ -, κ -, dan ι -karagenan dengan M ^{pro} SARS-CoV-2....	54
4.3.2. Interaksi Molekuler λ -, κ -, dan ι -karagenan dengan M ^{pro} SARS-CoV-2.....	55
4.3.2.1. Visualisasi Sisi Pengikatan λ -, κ -, dan ι -karagenan dengan M ^{pro} SARS-CoV-2	55
4.3.2.2. Ikatan dan Interaksi yang Terbentuk antara λ -, κ -, dan ι -karagenan dengan M ^{pro} SARS-CoV-2.....	56
4.4. Potensi λ -, κ -, dan ι -karagenan Sebagai Kandidat Antivirus SARS-CoV-2 Berdasarkan Interaksinya dengan Reseptor ACE2, RBD SARS-CoV-2, dan M ^{pro} SARS-CoV-2.....	65
BAB V	68
A. Kesimpulan.....	68
B. Rekomendasi	69

DAFTAR PUSTAKA	70
LAMPIRAN.....	80

DAFTAR PUSTAKA

- Ahmadi, A., Zorofchian Moghadamtousi, S., Abubakar, S., & Zandi, K. (2015). Antiviral potential of algae polysaccharides isolated from marine sources: A review. *BioMed Research International*, 2015. <https://doi.org/10.1155/2015/825203>
- Atkins, P., & Depaula, J. (2006). *Physical Chemistry, 8th edition*. Oxford Press.
- Bárcena, M., Oostergetel, G. T., Bartelink, W., Faas, F. G. A., Verkleij, A., Rottier, P. J. M., Koster, A. J., & Bosch, B. J. (2009). Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirus. *Proceedings of the National Academy of Sciences of the United States of America*, 106(2), 582–587. <https://doi.org/10.1073/pnas.0805270106>
- Baspinar, A., Cukuroglu, E., Nussinov, R., Keskin, O., & Gursoy, A. (2014). PRISM: a web server and repository for prediction of protein – protein interactions and modeling their 3D complexes. *Nucleic Acids Research*, 42(May), 285–289. <https://doi.org/10.1093/nar/gku397>
- Baudoux, P., Carrat, C., Besnardeau, L., Charley, B., & Laude, H. (1998). Coronavirus Pseudoparticles Formed with Recombinant M and E Proteins Induce Alpha Interferon Synthesis by Leukocytes. *Journal of Virology*, 72(11), 8636–8643. <https://doi.org/10.1128/jvi.72.11.8636-8643.1998>
- Bos, E. C. W., Luytjes, W., Meulen, H. V. A. N. D. E. R., Koerten, H. K., & Spaan, W. J. M. (1996). *The Production of Recombinant Infectious D-Particles of a Murine Coronavirus in the Absence of Helper Virus*. 60(218), 52–60.
- Bronowska, A. K. (2011). Thermodynamics of ligand-protein interactions: implications for molecular design. In *Thermodynamics-Interaction Studies-Solids, Liquids and Gases*. IntechOpen.
- Buck, C. B., Thompson, C. D., Roberts, J. N., Müller, M., Lowy, D. R., & Schiller, J. T. (2006). Carrageenan is a potent inhibitor of papillomavirus infection. *PLoS Pathogens*, 2(7), 0671–0680. <https://doi.org/10.1371/journal.ppat.0020069>
- Buckingham, A. D., Fowler, P. W., & Hutson, J. M. (1988). Theoretical studies of van der Waals molecules and intermolecular forces. *Chemical Reviews*, 88(6), 963–988.
- Carlucci, M J, Scolaro, L. A., Nosedà, M. D., Cerezo, A. S., & Damonte, E. B. (2004). Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. *Antiviral Research*, 64(2), 137–141.
- Carlucci, María J., Scolaro, L. A., Errea, M. I., Matulewicz, M. C., & Damonte, E. B. (1997). Antiviral activity of natural sulphated galactans on herpes virus multiplication in cell culture. *Planta Medica*, 63(5), 429–432.

<https://doi.org/10.1055/s-2006-957727>

- Carlucci, Maria J, Pujol, C. A., Ciancia, M., Nosedá, M. D., Matulewicz, M. C., Damonte, E. B., & Cerezo, A. S. (1997). Antiherpetic and anticoagulant properties of carrageenans from the red seaweed *Gigartina skottsbergii* and their cyclized derivatives: correlation between structure and biological activity. *International Journal of Biological Macromolecules*, 20(2), 97–105.
- Carlucci, Maria Josefina, Scolaro, L. A., & Damonte, E. B. (2002). Herpes simplex virus type 1 variants arising after selection with an antiviral carrageenan: lack of correlation between drug susceptibility and syn phenotype. *Journal of Medical Virology*, 68(1), 92–98.
- Chow, W. A., Jiang, C., & Guan, M. (2009). Anti-HIV drugs for cancer therapeutics: back to the future? *The Lancet Oncology*, 10(1), 61–71. [https://doi.org/10.1016/S1470-2045\(08\)70334-6](https://doi.org/10.1016/S1470-2045(08)70334-6)
- Correa, J. A., Beltrán, J., Buschmann, A. H., & Westermeier, R. (1999). Healing and regeneration responses in *Gigartina skottsbergii* (Rhodophyta, Gigartinales): Optimization of vegetative propagation for cultivation. *Journal of Applied Phycology*, 11(3), 315–327. <https://doi.org/10.1023/A:1008106527820>
- De Clercq, E. (2004). Antiviral drugs in current clinical use. *Journal of Clinical Virology*, 30(2), 115–133. <https://doi.org/10.1016/j.jcv.2004.02.009>
- De Haan, C. A. M., De Wit, M., Kuo, L., Montalto-Morrison, C., Haagmans, B. L., Weiss, S. R., Masters, P. S., & Rottier, P. J. M. (2003). The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. *Virology*, 312(2), 395–406. [https://doi.org/10.1016/S0042-6822\(03\)00235-6](https://doi.org/10.1016/S0042-6822(03)00235-6)
- de Haan, C. A. M., Kuo, L., Masters, P. S., Vennema, H., & Rottier, P. J. M. (1998). Coronavirus Particle Assembly: Primary Structure Requirements of the Membrane Protein. *Journal of Virology*, 72(8), 6838–6850. <https://doi.org/10.1128/jvi.72.8.6838-6850.1998>
- DeDiego, M. L., Álvarez, E., Almazán, F., Rejas, M. T., Lamirande, E., Roberts, A., Shieh, W.-J., Zaki, S. R., Subbarao, K., & Enjuanes, L. (2007). A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo. *Journal of Virology*, 81(4), 1701–1713. <https://doi.org/10.1128/jvi.01467-06>
- Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., Breitbart, R. E., & Acton, S. (2000). A Novel Angiotensin-Converting Enzyme – Related to Angiotensin 1-9. *Circulation Research*, 87(5), 1–10.
- Gao, J., & Hu, S. (2020). Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). *BioScience Trends*, 14(2), 156–

Diah Nurhayati, 2020

KAJIAN POTENSI KARAGENAN DARI *Gigartina skottsbergii* SEBAGAI KANDIDAT ANTIVIRUS SARS-CoV-2 MENGGUNAKAN SIMULASI MOLECULAR DOCKING

Universitas Pendidikan Indonesia | repository.upi.edu | perpustakaan.upi.edu

158. <https://doi.org/10.5582/bst.2020.03072>

- Ghosh, T., Chattopadhyay, K., Marschall, M., Karmakar, P., Mandal, P., & Ray, B. (2009). Focus on antivirally active sulfated polysaccharides: From structure-activity analysis to clinical evaluation. *Glycobiology*, *19*(1), 2–15. <https://doi.org/10.1093/glycob/cwn092>
- Gómez-Jeria, J. S., Robles-Navarro, A., Kpotin, G. A., Garrido-Sáez, N., & Gatica-Díaz, N. (2020). Some remarks about the relationships between the common skeleton concept within the Klopman-Peradejordi-Gómez QSAR method and the weak molecule-site interactions. *Chemistry Research Journal*, *5*(2), 32–52.
- Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., Penzar, D., Perlman, S., Poon, L. L. M., Samborskiy, D. V., Sidorov, I. A., Sola, I., & Ziebuhr, J. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*, *5*(4), 536–544. <https://doi.org/10.1038/s41564-020-0695-z>
- Graham, R. L., & Baric, R. S. (2010). Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission. *Journal of Virology*, *84*(7), 3134–3146. <https://doi.org/10.1128/jvi.01394-09>
- Grassauer, A., Weinmuellner, R., Meier, C., Pretsch, A., Prieschl-Grassauer, E., & Unger, H. (2008). Iota-Carrageenan is a potent inhibitor of rhinovirus infection. *Virology Journal*, *5*, 5–7. <https://doi.org/10.1186/1743-422X-5-107>
- Guedes, I. A., Magalhães, C. S. De, & Dardenne, L. E. (2013). *Receptor – ligand molecular docking*. <https://doi.org/10.1007/s12551-013-0130-2>
- Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak an update on the status. *Military Medical Research*, *7*(11). <https://doi.org/10.1093/eurheartj/ehaa396>
- He, J. F., Peng, G. W., Min, J., Yu, D. W., Liang, W. J., Zhang, S. Y., Xu, R. H., Zheng, H. Y., Wu, X. W., Xu, J., Wang, Z. H., Fang, L., Zhang, X., Li, H., Yan, X. G., Lu, J. H., Hu, Z. H., Huang, J. C., Wan, Z. Y., ... Lo, Y. M. D. (2004). Molecular Evolution of the SARS Coronavirus, during the Course of the SARS Epidemic in China. *Science*, *303*(5664), 1666–1669. <https://doi.org/10.1126/science.1092002>
- Hernandez-Carmona, G., Freile-Pelegrín, Y., & Hernández-Garibay, E. (2013). Conventional and alternative technologies for the extraction of algal polysaccharides. In *Functional ingredients from algae for foods and nutraceuticals* (pp. 475–516). Elsevier.

Diah Nurhayati, 2020

KAJIAN POTENSI KARAGENAN DARI *Gigartina skottsbergii* SEBAGAI KANDIDAT ANTIVIRUS SARS-CoV-2 MENGGUNAKAN SIMULASI MOLECULAR DOCKING

Universitas Pendidikan Indonesia | repository.upi.edu | perpustakaan.upi.edu

- Hevener, K. E., Zhao, W., Ball, D. M., Babaoglu, K., Qi, J., White, S. W., & Lee, R. E. (2009). Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. *J. Chem. Inf. Model.*, 444–460. <https://doi.org/10.1016/B978-008055232-3.60524-0>
- Holmes, K. V., Doller, E. W., & Sturman, L. S. (1981). Tunicamycin resistant glycosylation of a coronavirus glycoprotein: Demonstration of a novel type of viral glycoprotein. *Virology*, 115(2), 334–344. [https://doi.org/10.1016/0042-6822\(81\)90115-X](https://doi.org/10.1016/0042-6822(81)90115-X)
- Huey, R., Morris, G. M., & Forli, S. (2012). Using AutoDock 4 and AutoDock Vina with AutoDockTools : A Tutorial. *The Scripps Research Institute*.
- Jeffrey, G. A. (1997). *An Introduction to Hydrogen Bonding By George A. Jeffrey (University of Pittsburgh). Oxford University Press: New York and Oxford. 1997. ix+ 303 pp. \$60.00. ISBN 0-19-509549-9. ACS Publications.*
- Kim, R., & Skolnick, J. (2008). Assessment of programs for ligand binding affinity prediction. *Journal of Computational Chemistry*, 29(8), 1316–1331.
- Koenighofer, M., Lion, T., Bodenteich, A., Prieschl-grassauer, E., Grassauer, A., Unger, H., Mueller, C. A., & Fazekas, T. (2014). *Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.* 1–12.
- Kumar, R., Singh, C., Saifi, A., Kumar, S., & Kumar, B. (2020). Corona Virus, Precaution and Some Treatments. *American Journal of Biomedical Research*, 8(1), 15–18. <https://doi.org/10.12691/ajbr-8-1-3>
- Kuo, L., & Masters, P. S. (2003). *The Small Envelope Protein E Is Not Essential for Murine Coronavirus Replication.* 77(8), 4597–4608. <https://doi.org/10.1128/JVI.77.8.4597>
- Lahaye, M. (2001). Developments on gelling algal galactans, their structure and physico-chemistry. *Journal of Applied Phycology*, 13(2), 173–184. <https://doi.org/10.1023/A:1011142124213>
- Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, 581(7807), 215–220. <https://doi.org/10.1038/s41586-020-2180-5>
- Letko, M., Marzi, A., & Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nature Microbiology*, 5(4), 562–569. <https://doi.org/10.1038/s41564-020-0688-y>
- Lewicki, D. N., & Gallagher, T. M. (2002). Quaternary structure of coronavirus spikes in complex with carcinoembryonic antigen-related cell adhesion molecule cellular receptors. *Journal of Biological Chemistry*, 277(22), 19727–19734. <https://doi.org/10.1074/jbc.M201837200>

- Lin, S., Brasseur, J. G., Poudroux, P., & Kahrilas, P. J. (1995). The phrenic ampulla: distal esophagus or potential hiatal hernia? *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 268(2), G320–G327.
- Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery*, 6(1), 6–9. <https://doi.org/10.1038/s41421-020-0156-0>
- Lukitaningsih, E., Wisnusaputra, A., & Sudarmanto, B. S. A. (2009). Scrinig In Silico Active Compound Of Pachyrrhizus Erosus As Antitirosinase On *Aspergillus Oryzae* (Computattional Study With Homology Modeling And Molecular Docking). *Majalah Obat Tradisional (Traditional Medicine Journal)*, 20(1), 7–15.
- Lüscher-Mattii, M. (2000). Polyanions—a lost chance in the fight against HIV and other virus diseases? *Antiviral Chemistry and Chemotherapy*, 11(4), 249–259.
- McCandless, E. L., & Craigie, J. S. (1979). Sulfated Polysaccharides in Red and Brown Algae. *Annual Review of Plant Physiology*, 30(1), 41–53. <https://doi.org/10.1146/annurev.pp.30.060179.000353>
- Mcchesney, E. W., & Ph, D. (1993). *Animal Toxicity and Pharmacokinetics of Hydroxychloroquine Sulfate*. 11–18.
- Mengist, H. M., Fan, X., & Jin, T. (2020). Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro. *Signal Transduction and Targeted Therapy*, 5(1), 67. <https://doi.org/10.1038/s41392-020-0178-y>
- Mirza, M. U., & Froeyen, M. (2020). Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. *Journal of Pharmaceutical Analysis*.
- Morokutti-kurz, M., & Prieschl-grassauer, E. (2017). *hexylresorcinol , or carrageenan lozenges as active treatments for sore throat*.
- Morris, G M, Goodsell, D. S., Pique, M. E., Lindstrom, W., Huey, R., Forli, S., Hart, W. E., Halliday, S., Belew, R., & Olson, A. J. (2010). *User Guide AutoDock version 4.2. Automated Docking of Flexible Ligands to Flexible Receptors*. 2010.
- Morris, Garrett M., & Marguerita, L.-W. (2008). Molecular Docking : *Molecular Modeling of Proteins 1.1*, 1–5. https://doi.org/10.1007/3-540-29623-9_3820
- Morse, J. S., Lalonde, T., Xu, S., & Ray, W. (2020). *Learning from the Past : Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV ***. 730–738. <https://doi.org/10.1002/cbic.202000047>

- Moses, J., Anandhakumar, R., & Shanmugam, M. (2015). Effect of alkaline treatment on the sulfate content and quality of semi-refined carrageenan prepared from seaweed *Kappaphycus alvarezii* Doty (Doty) farmed in Indian waters. *African Journal of Biotechnology*, 14(18), 1584–1589.
- Munawaroh, H. S. H., Gumilar, G. G., Nurjanah, F., Yuliani, G., Aisyah, S., Kurnia, D., Wulandari, A. P., Kurniawan, I., Ningrum, A., & Koyandev, A. K. (2020). In-vitro molecular docking analysis of microalgae extracted phycocyanin as an anti-diabetic candidate. *Biochemical Engineering Journal*, 107666.
- NIAID-RML. (2020). *New Images of Novel Coronavirus SARS-CoV-2 Now Available*. <https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images>
- Niemann, H., Geyer, R., Klenk, H. D., Linder, D., Stirm, S., & Wirth, M. (1984). The carbohydrates of mouse hepatitis virus (MHV) A59: structures of the O-glycosidically linked oligosaccharides of glycoprotein E1. *The EMBO Journal*, 3(3), 665–670. <https://doi.org/10.1002/j.1460-2075.1984.tb01864.x>
- Noviardi, H., & Fachrurrazie. (2015). Potensi Senyawa Bullatalisin Sebagai Inhibitor Protein Leukotrien A4 Hidrolase Pada Kanker Kolon Secara In Silico. *Fitofarmaka*, 5(2), 65–73.
- Philp, K. (2018). Polysaccharide Ingredients. In *Reference Module in Food Science*. Elsevier. <https://doi.org/10.1016/b978-0-08-100596-5.22367-6>
- Raamsman, M. J. B., Locker, J. K., de Hooge, A., de Vries, A. A. F., Griffiths, G., Vennema, H., & Rottier, P. J. M. (2000). Characterization of the Coronavirus Mouse Hepatitis Virus Strain A59 Small Membrane Protein E. *Journal of Virology*, 74(5), 2333–2342. <https://doi.org/10.1128/jvi.74.5.2333-2342.2000>
- Rabi, F. A., Al Zoubi, M. S., Al-Nasser, A. D., Kasasbeh, G. A., & Salameh, D. M. (2020). Sars-cov-2 and coronavirus disease 2019: What we know so far. *Pathogens*, 9(3), 1–14. <https://doi.org/10.3390/pathogens9030231>
- Rachmania, R. A. S., & Larasati, O. A. (2015). Senyawa diterpenoid laktone herba sambiloto (*Andrographis paniculata* Nees) pada Reseptor Alpha-Glucosidase Sebagai Antidiabetes Tipe II. *Pharmacy*, 12(02), 210–222.
- Richman, D. D., Whitley, R. J., & Hayden, F. G. (2020). *Clinical virology*. John Wiley & Sons.
- Rodriguez, M. C., Merino, E. R., Pujol, C. A., Damonte, E. B., & Cerezo, A. S. (2005). Galactans from cystocarpic plants of the red seaweed (*Kallymeniaceae*, *Gigartinales*). 340, 2742–2751. <https://doi.org/10.1016/j.carres.2005.10.001>
- Rossignol, J. F. (2014). Nitazoxanide: A first-in-class broad-spectrum antiviral agent. *Antiviral Research*, 110(August), 94–103. <https://doi.org/10.1016/j.antiviral.2014.07.014>

- Sanchez, C. G., Molinski, S. V, Gongora, R., Sosulski, M., Fuselier, T., MacKinnon, S. S., Mondal, D., & Lasky, J. A. (2018). The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis. *Arthritis & Rheumatology (Hoboken, N.J.)*, 70(1), 115–126. <https://doi.org/10.1002/art.40326>
- Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *Jama*, 323(18), 1824–1836.
- Santoso, B. (2011). Docking Analog Kurkumin Turunan Piperazindion Dengan Tubulin (1tub) Rantai B Menggunakan Vina Dan Autodock. *PHARMACON*, 12(1), 14–18. <https://doi.org/10.1017/CBO9781107415324.004>
- Saputri, K. E., Fakhmi, N., Kusumaningtyas, E., Priyatama, D., & Santoso, B. (2016). Docking Molekular Potensi Anti Diabetes Melitus Tipe 2 Turunan Zerumbon Sebagai Inhibitor Aldosa Reduktase Dengan Autodock-Vina. *Chimica et Natura Acta*, 4(1), 16. <https://doi.org/10.24198/cna.v4.n1.10443>
- Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., & Cassone, A. (2006). New insights into the antiviral effects of chloroquine. *Lancet Infectious Diseases*, 6(2), 67–69. [https://doi.org/10.1016/S1473-3099\(06\)70361-9](https://doi.org/10.1016/S1473-3099(06)70361-9)
- Schottel, B. L., Chifotides, H. T., Dunbar, K. R., Gale, P. A., García-garrido, S. E., Garric, J., Schottel, B. L., Chifotides, H. T., & Dunbar, K. R. (2008). *Anion- p interactions*. 37(1). <https://doi.org/10.1039/b614208g>
- Setchell, W.A. & Gardner, N. L. (1936). *Iridophycus* gen. nov. and its representation in South America. *Proceedings of the National Academy of Science of the United States of America*, 22(1), 469–473.
- Shen, K., Yang, Y., Wang, T., Zhao, D., Jiang, Y., Jin, R., & Zheng, Y. (2020). Diagnosis , treatment , and prevention of 2019 novel coronavirus infection in children: experts ’ consensus statement. *World Journal of Pediatrics*, 0123456789. <https://doi.org/10.1007/s12519-020-00343-7>
- Singhal, T. (2020). *Review on COVID19 disease so far*. 87(April), 281–286.
- Tahir, M., Alqahtani, S. M., Alamri, M. A., & Chen, L. (2020). Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants. *Journal of Pharmaceutical Analysis*, xxx, 1–7. <https://doi.org/10.1016/j.jpha.2020.03.009>
- Talarico, L. B., & Damonte, E. B. (2007). Interference in dengue virus adsorption and uncoating by carrageenans. *Virology*, 363(2), 473–485. <https://doi.org/10.1016/j.virol.2007.01.043>
- Talarico, L. B., Nosedá, M. D., Ducatti, D. R. B., Duarte, M. E. R., & Damonte, E. B. (2011). Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. *Journal of General Virology*, 92(6), 1332–1342.

- Talarico, L. B., Zibetti, R. G. M., Faria, P. C. S., Scolaro, L. A., Duarte, M. E. R., Nosedá, M. D., Pujol, C. A., & Damonte, E. B. (2004). Anti-herpes simplex virus activity of sulfated galactans from the red seaweeds *Gymnogongrus griffithsiae* and *Cryptonemia crenulata*. *International Journal of Biological Macromolecules*, 34(1–2), 63–71. <https://doi.org/10.1016/j.ijbiomac.2004.03.002>
- Tan, Y. J., Lim, S. G., & Hong, W. (2005). Characterization of viral proteins encoded by the SARS-coronavirus genome. *Antiviral Research*, 65(2), 69–78. <https://doi.org/10.1016/j.antiviral.2004.10.001>
- Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000). A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase. *Journal of Biological Chemistry*, 275(43), 33238–33243. <https://doi.org/10.1074/jbc.M002615200>
- Tischer, P. C. de S., Talarico, L. B., Nosedá, M. D., Silvia, S. M., Damonte, E. B., & Duarte, M. E. R. (2006). Chemical structure and antiviral activity of carrageenans from *Meristiella gelidium* against herpes simplex and dengue virus. *Carbohydrate Polymers*, 63(4), 459–465. <https://doi.org/10.1016/j.carbpol.2005.09.020>
- Trott, O., & Olson, A. J. (2009). Software News and Update AutoDock Vina : Improving the Speed and Accuracy of Docking with a New Scoring Function , Efficient Optimization , and Multithreading. *Journal Of Computational Chemistry*. <https://doi.org/10.1002/jcc>
- Trottet, L., Owen, H., Holme, P., Heylings, J., Collin, I. P., Breen, A. P., Siyad, M. N., Nandra, R. S., & Davis, A. F. (2005). Are all aciclovir cream formulations bioequivalent? *International Journal of Pharmaceutics*, 304(1–2), 63–71. <https://doi.org/10.1016/j.ijpharm.2005.07.020>
- Tuncbag, N., Gursoy, A., Nussinov, R., & Keskin, O. (2011). Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. *Nature Protocols*, 6(9), 1341–1354. <https://doi.org/10.1038/nprot.2011.367>
- Vennema, H., Godeke, G. J., Rossen, J. W., Voorhout, W. F., Horzinek, M. C., Opstelten, D. J., & Rottier, P. J. (1996). Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. *The EMBO Journal*, 15(8), 2020–2028. <https://doi.org/10.1002/j.1460-2075.1996.tb00553.x>
- Vera, J., Castro, J., Gonzalez, A., & Moenne, A. (2011). Seaweed polysaccharides and derived oligosaccharides stimulate defense responses and protection against pathogens in plants. *Marine Drugs*, 9(12), 2514–2525. <https://doi.org/10.3390/md9122514>
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the

- recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research*, 30(3), 269–271. <https://doi.org/10.1038/s41422-020-0282-0>
- Wang, W., Wang, S. X., & Guan, H. S. (2012). The antiviral activities and mechanisms of marine polysaccharides: An overview. *Marine Drugs*, 10(12), 2795–2816. <https://doi.org/10.3390/md10122795>
- Weniger, H. (1979). Review of side effects and toxicity of chloroquine. In *World Health* (pp. 1–26).
- Wissink, E. H. J., Kroese, M. V., Maneschijn-Bonsing, J. G., Meulenberg, J. J. M., van Rijn, P. A., Rijsewijk, F. A. M., & Rottier, P. J. M. (2004). Significance of the oligosaccharides of the porcine reproductive and respiratory syndrome virus glycoproteins GP2a and GP5 for infectious virus production. *Journal of General Virology*, 85(12), 3715–3723. <https://doi.org/10.1099/vir.0.80402-0>
- Witvrouw, M., & De Clercq, E. (1997). Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. *General Pharmacology*, 29(4), 497–511. [https://doi.org/10.1016/S0306-3623\(96\)00563-0](https://doi.org/10.1016/S0306-3623(96)00563-0)
- Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 367(6483), 1260–1263. <https://doi.org/10.1126/science.aax0902>
- Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., Zheng, M., Chen, L., & Li, H. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*. <https://doi.org/10.1016/j.apsb.2020.02.008>
- Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., & Zhu, W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. *BioRxiv*, 1201, 2020.01.27.921627. <https://doi.org/10.1101/2020.01.27.921627>
- Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K. F., Wei, Y., Jin, N., & Jiang, C. (2013). Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. *Cell Research*, 23(2), 300–302. <https://doi.org/10.1038/cr.2012.165>
- Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Medicine*, 46(4), 586–590. <https://doi.org/10.1007/s00134-020-05985-9>
- Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors.

Science, 368(6489), 409–412. <https://doi.org/10.1126/science.abb3405>

Zhou, P., Yang, X. Lou, Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. Di, Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., ... Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 579(7798), 270–273. <https://doi.org/10.1038/s41586-020-2012-7>

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*, 8(382), 727–733. <https://doi.org/10.1056/NEJMoa2001017>